| Literature DB >> 35010951 |
Deborah Armborst1, Norman Bitterlich2, Birgit Alteheld3, Daniela Rösler4, Christine Metzner4,5, Roswitha Siener1.
Abstract
Chronic psychological stress can result in physiological and mental health risks via the activation of the hypothalamic-pituitary-adrenal (HPA) axis, sympathoadrenal activity and emotion-focused coping strategies. The impact of different stress loads on cardiometabolic risk is poorly understood. This post hoc analysis of a randomized pilot study was conducted on 61 participants (18-65 years of age) with perceived chronic stress. The Perceived Stress Questionnaire (PSQ30), Psychological Neurological Questionnaire (PNF), anthropometric, clinical and blood parameters were assessed. Subjects were assigned to 'high stress' (HS; PSQ30 score: 0.573 ± 0.057) and 'very high stress' (VHS; PSQ30 score: 0.771 ± 0.069) groups based on the PSQ30. Morning salivary cortisol and CRP were elevated in both groups. Visceral adiposity, elevated blood pressure and metabolic syndrome were significantly more frequent in the HS group vs. the VHS group. The fatty liver index (FLI) was higher (p = 0.045), while the PNF score was lower (p < 0.001) in the HS group. The HS group was comprised of more smokers (p = 0.016). Energy intake and physical activity levels were similar in both groups. Thus, high chronic stress was related to visceral adiposity, FLI, elevated blood pressure and metabolic syndrome in the HS group, while very high chronic stress was associated with psychological-neurological symptoms and a lower cardiometabolic risk in the VHS group, probably due to different coping strategies.Entities:
Keywords: cardiometabolic risk; coping strategies; fatty liver index (FLI); hypothalamic–pituitary–adrenal (HPA) axis; perceived stress questionnaire (PSQ30); psychological neurological questionnaire (PNF); stress habituation; stress management; visceral adiposity
Mesh:
Substances:
Year: 2021 PMID: 35010951 PMCID: PMC8747048 DOI: 10.3390/nu14010077
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Characteristics of participants.
| ITT Population | HS Group (1) | VHS Group (2) | HS vs. VHS | |
|---|---|---|---|---|
| Age (years) | 44.6 ± 12.1 | 45.3 ± 12.1 | 43.7 ± 12.3 | 0.559 |
| Women | 43 (70.5%) | 21 (67.7%) | 22 (73.3%) | 0.780 |
| Men | 18 (29.5%) | 10 (32.3%) | 8 (26.7%) | |
| Smokers | 15 (24.6%) | 12 (38.7%) | 3 (10.0%) | 0.016 |
| Total PSQ30 score | 0.671 ± 0.118 | 0.573 ± 0.057 | 0.771 ± 0.069 | <0.001 |
| PNF (total) | 51.3 ± 12.1 | 46.2 ± 10.9 | 56.6 ± 11.2 | <0.001 |
|
| ||||
| Married/cohabitation | 31 (50.8%) | 14 (45.2%) | 17 (56.7%) | 0.373 |
| Single | 17 (27.9%) | 11 (35.5%) | 6 (20.0%) | |
| Separated | 12 (19.7%) | 6 (19.4%) | 6 (20.0%) | |
|
| ||||
| 0 children | 32 (52.5%) | 16 (51.6%) | 16 (53.3%) | 0.445 |
| 1 child | 15 (24.6%) | 10 (32.3%) | 5 (16.7%) | |
| 2 children | 9 (14.8%) | 3 (9.7%) | 6 (20.0%) | |
| ≥3 children | 4 (6.6%) | 2 (6.5%) | 2 (6.7%) | |
|
| ||||
| Yes | 17 (27.9%) | 9 (29.0%) | 8 (26.7%) | 1.000 |
| No | 42 (68.9%) | 21 (67.7%) | 21 (70.0%) | |
|
| ||||
| Yes | 14 (23.0%) | 6 (19.4%) | 8 (26.7%) | 0.554 |
| No | 47 (77.0%) | 25 (80.6%) | 22 (73.3%) | |
|
| ||||
| No | 14 (23.0%) | 10 (32.3%) | 4 (13.3%) | 0.127 |
| Yes | 47 (77.0%) | 21 (67.7%) | 26 (86.7%) | |
| Yes: athletic and endurance sports | 20 (32.8%) | 8 (25.8%) | 12 (41.4%) | 0.283 |
| Yes: low-intensity endurance sports | 21 (34.4%) | 9 (29.0%) | 12 (40.0%) | 0.426 |
| Yes: autogenous training or yoga | 6 (9.8%) | 4 (12.9%) | 2 (6.7%) | 0.671 |
Abbreviations: IIT, intention-to-treat population; PNF, Psychological Neurological Questionnaire; PSQ, Perceived Stress Questionnaire; SD, standard deviation. (1) High stress (HS) group: participants with a total PSQ30 score of 0.500–0.656; (2) Very high stress (VHS) group: participants with a total PSQ30 score > 0.656; (3) one person did not answer the question because of personal reasons; (4) two persons did not answer the question because of personal reasons; p Value: Mann–Whitney U test or Fisher’s exact test.
Cardiometabolic risk of participants.
| ITT Population | HS Group (1)
| VHS Group (2)
| HS vs. VHS | |
|---|---|---|---|---|
|
| ||||
| BMI (kg/m2) | 25.5 ± 5.1 | 26.6 ± 6.0 | 24.4 ± 3.71 | 0.169 |
| WC (cm)_women | 86.3 ± 12.4 | 89.7 ± 14.3 | 83.4 ± 9.44 | 0.079 |
| WC (cm)_men | 101.7 ± 13.6 | 106.1 ± 16.3 | 96.2 ± 6.67 | 0.051 |
| BP systolic (mmHg) | 112.1 ± 14.2 | 115.2 ± 14.7 | 109.0 ± 13.1 | 0.094 |
| BP diastolic (mmHg) | 75.2 ± 8.5 | 76.6 ± 8.7 | 73.7 ± 8.2 | 0.141 |
| Resting heart rate (1/min) | 66.5 ± 8.5 | 66.2 ± 7.7 | 66.9 ± 9.5 | 0.906 |
|
| ||||
| BMI ≥ 30.0 kg/m2 | 11 (18.0%) | 8 (25.8%) | 3 (10.0%) | 0.182 |
| WC ≥ 88 cm (w/≥ 102 cm (m)) | 28 (45.9%) | 20 (64.5%) | 8 (26.7%) | 0.005 |
| BP ≥ 130/85 mmHg | 11 (18.0%) | 9 (29.0%) | 2 (6.7%) | 0.043 |
| TC (mg/dL) | 212.2 ± 46.9 | 217.0 ± 45.4 | 207.2 ± 48.8 | 0.372 |
| TC > 200 | 35 (57.4%) | 21 (67.7%) | 14 (46.7%) | 0.124 |
| HDL-C (mg/dL) | 64.7 ± 19.8 | 60.2 ± 17.1 | 69.4 ± 21.6 | 0.117 |
| HDL-C < 50 (w)/< 40 (m) | 14 (23.0%) | 7 (22.6%) | 7 (23.3%) | 1.000 |
| LDL-C (mg/dL) | 134.2 ± 41.6 | 140.1 ± 39.4 | 128.1 ± 43.6 | 0.261 |
| LDL-C ≥ 175 | 11 (18.0%) | 6 (19.4%) | 5 (16.7%) | 1.000 |
| TG (mg/dL) | 100.1 ± 53.7 | 111.8 ± 68.4 | 88.1 ± 28.9 | 0.249 |
| TG ≥ 150 | 6 (9.8%) | 5 (16.1%) | 1 (3.3%) | 0.195 |
| Fasting plasma glucose (mg/dL) | 89.7 ± 17.1 | 91.7 ± 22.2 | 87.7 ± 9.2 | 0.923 |
| FPG ≥ 100 (mg/dL) | 7 (11.5%) | 5 (16.1%) | 2 (6.7%) | 0.425 |
| HbA1c (%) | 5.5 ± 0.6 | 5.6 ± 0.7 | 5.4 ± 0.3 | 0.179 |
| HOMA index | 1.7 ± 1.5 | 2.1 ± 2.0 | 1.3 ± 0.6 | 0.184 |
| Insulin–ECLIA (μU/mL) | 7.3 ± 4.2 | 8.3 ± 4.9 | 6.2 ± 3.0 | 0.107 |
| Metabolic syndrome (NCEP [ | 6 (9.8%) | 6 (19.4%) | 0 (0%) | 0.024 |
| ALAT (U/L) | 23.7 ± 12.0 | 24.94 ± 12.8 | 22.5 ± 11.1 | 0.540 |
| ASAT (U/L) | 25.2 ± 12.6 | 26.8 ± 17.2 | 23.5 ± 4.1 | 0.860 |
| FLI | 33.5 ± 28.4 | 42.5 ± 31.9 | 24.1 ± 21.1 | 0.045 |
| FLI ≥ 30 | 28 (45.9%) | 19 (61.3%) | 9 (30.0%) | 0.021 |
| FLI ≥ 60 | 14 (23.0%) | 10 (32.3%) | 4 (13.3%) | 0.127 |
| Atherogenic dyslipoproteinemia | 3 (4.9%) | 3 (9.7%) | 0 (0%) | 0.238 |
| TC/HDL-C | 3.5 ± 1.2 | 3.9 ± 1.4 | 3.2 ± 0.9 | 0.022 |
| LDL-C/HDL-C | 2.3 ± 1.0 | 2.5 ± 1.0 | 2.0 ± 0.8 | 0.030 |
|
| ||||
| Serum serotonin (μg/L) | 144.3 ± 69.2 | 135.4 ± 47.8 | 153.4 ± 85.8 | 0.734 |
| Cortisol_morning (ng/mL) | 13.8 ± 5.7 | 14.0 ± 6.0 | 13.6 ± 5.5 | 0.783 |
| Cortisol_evening (ng/mL) | 2.5 ± 3.8 | 2.7 ± 3.7 | 2.3 ± 3.9 | 0.544 |
| Δ cortisol (m–e) (ng/mL) | 11.3 ± 6.0 | 11.3 ± 6.9 | 11.3 ± 5.1 | 0.997 |
|
| ||||
| CRP sensitive (mg/L) | 2.2 ± 3.4 | 2.0 ± 2.9 | 2.4 ± 3.9 | 0.821 |
| Ferritin (ng/mL) | 114.9 ± 106.9 | 116.6 ± 132.5 | 113.1 ± 74.2 | 0.458 |
| GGT (U/L) | 22.2 ± 13.2 | 25.1 ± 15.0 | 19.3 ± 10.6 | 0.142 |
| Folic acid (ng/mL) (3) | 9.6 ± 3.6 | 9.4 ± 3.8 | 9.8 ± 3.4 | 0.438 |
| Uric acid (mg/dL) | 4.8 ± 1.1 | 5.0 ± 1.1 | 4.6 ± 1.1 | 0.179 |
Abbreviations: ALAT, alanine aminotransferase; ASAT, aspartate aminotransferase; BMI, body mass index; BP, blood pressure; Δ cortisol (m–e), cortisol difference morning–evening; CRP, C-reactive protein; ECLIA, electrochemiluminescence immunoassay; FLI, fatty liver index; FPG, fasting plasma glucose; GGT, gamma-glutamyltransferase; HbA1c, glycated hemoglobin A1c; HDL-C, high-density lipoprotein cholesterol; HOMA index, homeostasis model assessment index; ITT, intention-to-treat population; LDL-C, low-density lipoprotein cholesterol; NCEP, National Cholesterol Education Program; SD, standard deviation; TC, total cholesterol; TG, triglycerides; WC, waist circumference. (1) High stress (HS) group: participants with a total PSQ30 score of 0.500–0.656; (2) Very high stress (VHS) group: participants with a total PSQ30 score > 0.656; (3) n = 60, data not available for one participant (hemolytic blood sample); p Value: Mann–Whitney U test or Fisher’s exact test.
Figure 1The relationship of the chronic perceived stress load and the cardiometabolic risk in the ITT population. The relationships between the total PSQ30 score (independent variable) and the dependent variables (a) fatty liver index, (b) LDL-C/HDL-C quotient and (c) insulin concentration were examined. Results for the high stress (HS) group (n = 31), the very high stress (VHS) group (n = 30), and the cut-off value (dashed line) for FLI and LDL-C/HDL-C quotient are shown. Regression lines: (a) Beta value = −0.266, p = 0.038, 95% confidence interval: −125.1 to −3.7; (b) Beta value = −0.294, p = 0.022, 95% confidence interval: −4.5 to −0.4; (c) Beta value = −0.330, p = 0.009, 95% confidence interval: −20.6 to −3.0.
Relationship of cardiometabolic risk parameters and in-/direct markers of inflammation and oxidative stress (age adjusted).
| CRP | Uric Acid | FLI | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ITT | HS Group (1) | VHS Group (2) | ITT | HS Group (1) | VHS Group (2) | ITT | HS Group (1) | VHS Group (2) | ||||||||||
| RCB | RCB | RCB | RCB | RCB | RCB | RCB | RCB | RCB | ||||||||||
| Weight (kg) | 0.054 | 0.033 | 0.054 | 0.057 | 0.073 | 0.160 | 0.038 | <0.001 | 0.036 | 0.001 | 0.040 | 0.003 | 1.366 | <0.001 | 1.298 | <0.001 | 1.255 | <0.001 |
| WC (cm) | 0.066 | 0.045 | 0.081 | 0.022 | 0.072 | 0.328 | 0.039 | <0.001 | 0.036 | 0.010 | 0.045 | 0.020 | 1.805 | <0.001 | 1.720 | <0.001 | 1.722 | <0.001 |
| BMI (kg/m2) | 0.204 | 0.020 | 0.185 | 0.052 | 0.370 | 0.072 | 0.090 | 0.001 | 0.082 | 0.029 | 0.101 | 0.070 | 4.694 | <0.001 | 4.228 | <0.001 | 5.053 | <0.001 |
| Syst. BD (mmHg) | 0.019 | 0.568 | −0.010 | 0.810 | 0.055 | 0.342 | 0.036 | <0.001 | 0.019 | 0.262 | 0.052 | <0.001 | 0.834 | 0.001 | 0.513 | 0.216 | 0.726 | 0.014 |
| Diast. BD (mmHg) | 0.058 | 0.277 | 0.009 | 0.894 | 0.121 | 0.189 | 0.041 | 0.017 | 0.011 | 0.689 | 0.065 | 0.006 | 1.428 | <0.001 | 1.089 | 0.086 | 1.249 | 0.008 |
| Heart rate (1/min) | 0.108 | 0.038 | 0.003 | 0.965 | 0.180 | 0.021 | 0.012 | 0.497 | 0.004 | 0.890 | 0.016 | 0.466 | 0.812 | 0.049 | 1.179 | 0.084 | 0.426 | 0.326 |
| Insulin (μU/mL) | 0.279 | 0.007 | 0.158 | 0.157 | 0.779 | 0.001 | 0.095 | 0.005 | 0.091 | 0.036 | 0.082 | 0.245 | 3.738 | <0.001 | 3.773 | <0.001 | 1.524 | 0.271 |
| HOMA index | 0.494 | 0.088 | 0.283 | 0.294 | 3.495 | 0.002 | 0.250 | 0.007 | 0.202 | 0.054 | 0.509 | 0.118 | 9.889 | <0.001 | 8.583 | <0.001 | 8.555 | 0.184 |
| FPG (mg/dL) | 0.017 | 0.527 | 0.016 | 0.530 | 0.038 | 0.670 | 0.022 | 0.013 | 0.017 | 0.077 | 0.043 | 0.072 | 0.801 | <0.001 | 0.767 | <0.001 | 0.619 | 0.190 |
| HbA1c (%) | 0.454 | 0.572 | 0.373 | 0.613 | 2.447 | 0.451 | 0.437 | 0.093 | 0.274 | 0.345 | 1.703 | 0.046 | 17.633 | 0.004 | 15.368 | 0.025 | 27.970 | 0.100 |
| TG (mg/dL) | 0.027 | 0.001 | 0.031 | <0.001 | 0.032 | 0.223 | 0.007 | 0.006 | 0.006 | 0.076 | 0.013 | 0.075 | 0.290 | <0.001 | 0.226 | 0.003 | 0.354 | 0.008 |
| HDL-C (mg/dL) | −0.066 | 0.004 | −0.086 | 0.004 | −0.068 | 0.073 | −0.029 | <0.001 | −0.022 | 0.079 | −0.033 | 0.001 | −0.903 | <0.001 | −1.100 | <0.001 | −0.548 | 0.005 |
| Serotonin (μg/L) | −0.006 | 0.399 | −0.015 | 0.214 | −0.003 | 0.704 | −0.005 | 0.029 | −0.008 | 0.075 | −0.003 | 0.199 | −0.112 | 0.029 | −0.082 | 0.492 | −0.088 | 0.560 |
| Vitamin E (mg) | 0.061 | 0.338 | 0.029 | 0.746 | 0.076 | 0.436 | 0.029 | 0.165 | 0.024 | 0.507 | 0.034 | 0.198 | 0.512 | 0.308 | 0.374 | 0.671 | 0.426 | 0.417 |
| Vitamin C (mg) | 0.002 | 0.658 | −0.005 | 0.639 | 0.004 | 0.575 | 0.001 | 0.398 | 0.002 | 0.651 | 0.002 | 0.385 | 0.029 | 0.486 | −0.004 | 0.965 | 0.049 | 0.187 |
| Folic acid (ng/mL) (3) | −0.049 | 0.705 | −0.257 | 0.076 | 0.202 | 0.386 | 0.001 | 0.349 | −0.017 | 0.768 | 0.120 | 0.044 | 0.980 | 0.340 | 0.140 | 0.923 | 2.397 | 0.043 |
| PFA (g) | −0.013 | 0.835 | 0.016 | 0.864 | −0.044 | 0.644 | 0.025 | 0.206 | 0.037 | 0.304 | 0.025 | 0.329 | 0.498 | 0.308 | 0.594 | 0.499 | 0.460 | 0.362 |
| Vitamin B12 (µg) | 0.034 | 0.789 | 0.267 | 0.100 | −0.136 | 0.511 | 0.066 | 0.114 | 0.156 | 0.012 | −0.022 | 0.697 | 1.917 | 0.055 | 3.714 | 0.015 | −0.065 | 0.954 |
| Total PSQ30 score | −0.008 | 0.998 | −1.960 | 0.848 | −8.574 | 0.439 | −1.918 | 0.123 | −6.943 | 0.078 | 1.049 | 0.729 | −63.95 | 0.032 | −102.2 | 0.297 | 16.23 | 0.785 |
Abbreviations: BMI, body mass index; BP (syst./diast.), systolic or diastolic blood pressure; CRP, C-reactive protein sensitive; FLI, fatty liver index; FPG, fasting plasma glucose; HbA1c, glycated hemoglobin A1c; HDL-C, high-density lipoprotein cholesterol; HOMA index, homeostasis model assessment index; (1) High stress (HS) group: participants with a total PSQ30 score of 0.500–0.656; (2) Very high stress (VHS) group: participants with a total PSQ30 score > 0.656. ITT, intention-to-treat population; PFA, polyunsaturated fatty acids; RCB, regression coefficient B; TG, triglycerides; WC, waist circumference. (3) n = 60, data not available for one participant (hemolytic blood sample); p value: linear regression analysis.
Coping strategies and cardiometabolic health of participants.
| ITT Population | HS Group (1) | VHS Group (2) | |||||||
|---|---|---|---|---|---|---|---|---|---|
|
| |||||||||
|
|
|
|
|
|
|
|
|
| |
| PSQ30 score | 0.619 ± 0.093 | 0.714 ± 0.120 | 0.003 | 0.573 ± 0.058 | 0.574 ± 0.058 | 0.992 | 0.735 ± 0.053 | 0.784 ± 0.070 | 0.072 |
| FLI | 51.8 ± 25.8 | 17.9 ± 20.3 | <0.001 | 56.1 ± 26.7 | 17.7 ± 25.5 | <0.001 | 40.9 ± 21.2 | 18.1 ± 17.9 | 0.005 |
| HOMA index | 2.3 ± 2.1 | 1.2 ± 0.5 | 0.002 | 2.7 ± 2.3 | 0.9 ± 0.4 | <0.001 | 1.4 ± 0.9 | 1.3 ± 0.5 | 0.738 |
| HbA1c (%) | 5.7 ± 0.8 | 5.4 ± 0.3 | 0.050 | 5.7 ± 0.9 | 5.5 ± 0.3 | 0.830 | 5.6 ± 0.2 | 5.3 ± 0.3 | 0.034 |
| CRP (mg/L) | 2.6 ± 3.6 | 1.8 ± 3.3 | 0.024 | 2.1 ± 2.0 | 1.8 ± 4.2 | 0.012 | 3.9 ± 6.0 | 1.8 ± 2.8 | 0.510 |
|
| |||||||||
|
|
|
|
|
|
|
|
|
| |
| PSQ30 score | 0.602 ± 0.091 | 0.693 ± 0.118 | 0.008 | 0.567 ± 0.054 | 0.578 ± 0.060 | 0.437 | 0.744 ± 0.062 | 0.774 ± 0.070 | 0.563 |
| HbA1c (%) | 5.7 ± 1.0 | 5.4 ± 0.3 | 0.643 | 5.9 ± 1.1 | 5.4 ± 0.3 | 0.270 | 5.1 ± 0.1 | 5.4 ± 0.3 | 0.024 |
| Uric acid (mg/dL) | 4.8 ± 1.1 | 4.8 ± 1.1 | 0.990 | 5.2 ± 1.0 | 4.9 ± 1.2 | 0.515 | 3.4 ± 0.3 | 4.7 ± 1.1 | 0.031 |
| CRP (mg/L) | 3.1 ± 3.8 | 1.9 ± 3.3 | 0.091 | 3.5 ± 4.2 | 1.1 ± 0.8 | 0.071 | 1.6 ± 1.2 | 2.5 ± 4.1 | 0.778 |
|
| |||||||||
|
|
|
|
|
|
|
|
|
| |
| PSQ30 score | 0.687 ± 0.116 | 0.614 ± 0.109 | 0.039 | 0.581 ± 0.058 | 0.558 ± 0.052 | 0.306 | 0.773 ± 0.069 | 0.755 ± 0.076 | 0.670 |
| HbA1c (%) | 5.4 ± 0.3 | 5.8 ± 1.0 | 0.060 | 5.4 ± 0.3 | 6.0 ± 1.2 | 0.194 | 5.4 ± 0.3 | 5.5 ± 0.2 | 0.293 |
| HDL-C (mg/dL) | 67.5 ± 17.4 | 55.2 ± 24.8 | 0.006 | 64.5 ± 16.9 | 51.1 ± 14.3 | 0.030 | 70.0 ± 17.7 | 65.4 ± 43.1 | 0.298 |
| Resting heart rate (1/min) | 65.0 ± 8.5 | 71.6 ± 6.7 | 0.008 | 63.6 ± 6.7 | 71.7 ± 6.8 | 0.006 | 66.2 ± 9.7 | 71.3 ± 7.4 | 0.305 |
Abbreviations: CRP, C-reactive protein sensitive; FLI, fatty liver index; HbA1c, glycated hemoglobin A1c; HDL-C, high-density lipoprotein cholesterol; HOMA index, homeostasis model assessment index; ITT, intention-to-treat population; PSQ, Perceived Stress Questionnaire; SD, standard deviation; (1) High stress group: participants with a total PSQ30 score of 0.500–0.656; (2) Very high stress group: participants with a total PSQ30 score > 0.656; p value: Mann–Whitney U test.